Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity

Authors not listed

Sara Espinoza · 2017

Abstract

Obesity is highly prevalent in older adults and is a major cause of sarcopenia and disability in older adults. Although exercise can counteract the effects of obesity and sarcopenia, many have difficulty adhering to an exercise program and the benefits of exercise are variable. Therefore, there is an urgent need to test novel pharmacologic interventions to prevent disability and loss of independence. Oxytocin is a pituitary hormone released during parturition and lactation that is also known to suppress appetite in rodents and humans; and, recent small studies have found that intranasal oxytocin reduces body weight in adults. We propose a pilot study of intranasal oxytocin as a novel approach to promote weight loss and increase muscle mass in older subjects with sarcopenic obesity.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-07-02 MST

Cite this

APA
Anonymous. (2017). The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity. <em>Sara Espinoza</em>. https://clinicaltrials.gov/study/NCT03119610
Vancouver
Anonymous. The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity. Sara Espinoza. 2017.
BibTeX
@misc{anon2017ThePhy, title = {The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity}, author = {Anonymous}, journal = {Sara Espinoza}, year = {2017}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.